Navigation Links
Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
Date:10/20/2010

ST. LOUIS, Oct. 20 /PRNewswire/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that it launched the Odyssey Interventional Network, a training and educational video sharing web portal for the global cardiovascular community.  The portal will showcase innovative electrophysiology (EP) and interventional cardiology (IC) procedures from leading centers around the world.  The Odyssey Interventional Network utilizes Stereotaxis' state-of-the-art Odyssey technology platform to deliver a synchronized, high-definition view of all information available during a procedure.  This allows specialists, referring doctors and patients an opportunity to virtually experience real interventional procedures and learn about the techniques of world-class clinical experts from the comfort of their home or office.    

The first online broadcast features a recorded EP procedure hosted by Dr. Andrea Natale, MD, FACC, FHRS and Dr. David Burkhardt, MD, FACC from the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, TX.  They performed a case on a 50-year old patient with significant coronary artery disease who had received multiple shocks from his implantable defibrillator for ventricular tachycardia (VT) despite medical therapy.  The patient was successfully treated during the procedure with the Stereotaxis Magnetic Navigation System as the doctors narrate the case.

The Odyssey Interventional Network represents a paradigm shift for the delivery of medical education.  Online procedures are often low-quality broadcasts with a limited view of the case.  Procedures that are broadcast on the Odyssey Interventional Network feature a complete, synchronized view of the many systems in the interventional lab in high definition, preserving the fine details of diagnostic and imaging data.

"Our Odyssey business is experiencing impressive growth as a workflow and information tool for cardiac catheterization labs (cath labs) and electrophysiology labs (EP labs) on a world-wide basis," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.  "In addition to its clear workflow and archiving advantages, many hospitals are acquiring the Odyssey solution to revolutionize their training and education programs.  We believe that the Odyssey Interventional Network provides a major breakthrough in online education with a high definition panoramic view of lab information for an optimized learning experience."

The Odyssey Interventional Network is currently a complementary service requiring a simple user registration.  It can be accessed through the company's Odyssey business website, www.odysseyexperience.com, or the newly expanded company website, www.stereotaxis.com.  Interested viewers can learn about upcoming cases at www.twitter.com/stereotaxis, or by joining Stereotaxis on Facebook.    

"The Odyssey Interventional Network addresses a significant unmet need in online clinical education for a broad audience," added Mr. Kaminski. "Our unique clinical technology will leverage the new social and interactive Internet in this manner to better meet the needs of our customers and patients."

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
2. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
3. Stereotaxis Announces Public Offering of Common Stock
4. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
5. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
7. Stereotaxis System Procedure Featured on NBCs The TODAY Show
8. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Installs First System in Taiwan
10. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
11. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology:
(Date:4/30/2017)... San Francisco, CA (PRWEB) , ... April 30, 2017 , ... ... Bay Area, is proud to announce an updated blog post on the continual issue ... are "too busy" to seek a second opinion before dental surgery, but this can ...
(Date:4/29/2017)... ... April 29, 2017 , ... Natural Family Planning ... observe the naturally occurring signs and symptoms of a woman's menstrual cycle. ... , Natural family planning and fertility are special interests of Dr. Bazger’s. She ...
(Date:4/29/2017)... UTAH (PRWEB) , ... April 29, 2017 , ... Phytomer ... region. As a Phytomer Account Manager, Smith’s role is to provide excellent ... brands that make up The Phytomer Group. Smith comes to Phytomer with a wealth ...
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... More than ... so what are Americans doing in their leisure time that causes hearing loss? May ... habits that may be contributing to hearing loss, as well as schedule a hearing ...
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
Breaking Medicine News(10 mins):